Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
synthetic haemophilus influenzae type b conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Changchun BCHT Biotechnology
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The synthetic haemophilus influenzae type b conjugate vaccine is a monovalent vaccine developed by Changchun Hiber Biotechnology Co., Ltd. for the prevention of invasive diseases caused by *Haemophilus influenzae* type b (Hib), such as meningitis, pneumonia, and epiglottitis. It is notable for being the first vaccine in China to utilize a chemically synthesized polyribosyl ribitol phosphate (PRP) oligosaccharide rather than one purified from bacterial cultures. This synthetic PRP is covalently conjugated to a tetanus toxoid carrier protein to convert the T-cell independent polysaccharide into a T-cell dependent antigen, thereby ensuring robust immunogenicity and the induction of immunological memory in infants and young children. The vaccine is typically administered via intramuscular injection and provides a highly defined and consistent antigenic profile due to its synthetic nature.
- Brand names
- Quimi-Hib
- Other names
- Synthetic Hib vaccineHib-TT (synthetic)Synthetic Haemophilus influenzae type b conjugate vaccine (TT)
Beyond the preview
Go deeper on synthetic haemophilus influenzae type b conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on synthetic haemophilus influenzae type b conjugate vaccine.